ODYY - Odyssey Health Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
(NewsDirect)
McapMediaWire --Odyssey Health, Inc. (OTC: ODYY ), f/k/a Odyssey GroupInternational, Inc., a company focused on creating unique,life-enhancing medical products, is developing a novelneuropharmaceutical treatment for mild Traumatic Brain Injury (mTBI)also known as a concussion. Recently, the world’s leading researchagency, the National Institutes of Health (NIH), acknowledged thatChronic Traumatic Encephalopathy (CTE) is caused by repetitive headtrauma, not uncommon in the field of sports and in our military.Odyssey’s lead drug candidate, ONP-002, is designed for the acutesetting using an intranasal neurosteroid that works to simultaneouslyreduce swelling, inflammation, and oxidative stress. Odyssey hascompleted a Phase I clinical trial and is now preparing for a Phase IIstudy to determine the safety and efficacy of its drug.
The National FootballLeague (NFL) announced an eighteen percent (18%) increase inconcussions sustained in the 2022 season compared to 2021, potentiallydue to the increased sideline concussion protocols. On average the NFLconducts 1.6 sideline concussion evaluations per game.
Data from a recentlycompleted study showed that older retired NFL players had an increasedrate of neurocognitive decline compared to non-players. Interestingly,a history of concussion where consciousness was lost had the greatesteffect on neurocognitive performance in older athletes. The NFL andNCAA continue to deal with legal claims surrounding concussions.
Internationally,Australian Rules footballers have recently brought legal actionagainst the league for downplaying the risk of head injury and failingto have proper protocols in place to protect the players. The cost tothe league could be as high as $2 million per player. The leaguerecently reversed its stance and now accepts that CTE is caused inpart by repetitive head trauma. In the past few years, concussions inelite rugby leagues have hit an all-time high since records kept. Overtwenty-two (22) concussions were documented per one thousand (1000)hours of rugby play. In a significant move, the leagues haveinstituted a 12-day no-play clause if the player is diagnosed with aconcussion.
“Given the reported incidences cited, Odyssey Healthrecognizes the urgent need to bring an effective pharmaceutical tomarket to treat the concussion epidemic. Not only are the therapeuticeffects of the drug vital, but there is a need for a field-deliverableand brain-targeted approach to the drug delivery. Our intranasaldelivery should optimize the success of the drug when given to ourathletes,” commented Michael Redmond, CEO for Odyssey Health,Inc.
AboutOdyssey Health Inc. (formerly Odyssey Group International,Inc.)
OdysseyHealth Inc. (OTC: ODYY) is a medical company with a focus onlife-saving medical solutions. Odyssey's corporate mission is tocreate, acquire and develop distinct assets, intellectual property,and exceptional technologies that provide meaningful medicalsolutions. The company is focused on areas that have an identifiedtechnological advantage, provide superior clinical utility, and have asubstantial market opportunity. For more information, visit theCompany’s website at www.odysseyhealthinc.com
We encourage ourshareholders to visit our corporate social media accounts forupdates:
AboutONP-002
ONP-002 is a fully synthetic non-naturally occurringneurosteroid being developed for the treatment of mTBI (concussion).In preclinical studies, ONP-002 has demonstrated equivalent, if notsuperior, neuroprotective effects compared to related neurosteroids.Animal models of concussion demonstrated that ONP-002 reduces thebehavioral pathology associated with brain injury symptoms such asmemory impairment, anxiety, and motor/sensory performance.Additionally, ONP-002 is lipophilic and can easily cross theblood-brain barrier to rapidly eliminate swelling, oxidative stressand inflammation in the brain while restoring proper blood flow. Ournovel breath-propelled, intranasal brain-drug delivery device isdesigned with a novel drug dispensing system that creates an effectiveairflow for depositing concentrated drug deep into the nasal cavityand onto the olfactory region, this could allow for quick and directdiffusion into the brain..
Forward-Looking Statements
This news release maycontain forward-looking statements within the meaning of the "safeharbor" provisions of the Private Securities Litigation Reform Actof 1995. Such statements are based upon our current expectations andspeak only as of the date hereof. Our actual results may differmaterially and adversely from those expressed in any forward-lookingstatements as a result of various factors and uncertainties, includingour ability to continue to raise needed funds, successfully completeclinical trial, our ability to successfully develop products, rapidchanges in our markets, changes in demand for our future products, andlegislative, regulatory, competitive developments and general economicconditions.
Inquiries:
Odyssey Health
ContactDetails
Odyssey Health
Copyright (c) 2023 TheNewswire - All rights reserved.